# Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Canonical URL: https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates
Ticker: MNPR
Company: Monopar
Source: Monopar
Published: 2026-05-14 18:00 EST
Original Source URL: https://ir.monopartx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-01 11:00 EST — [Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026](https://biopharmsignal.com/news/MNPR/monopar-presents-phase-2-alxn1840-data-demonstrating-liver-disease-stabilization-and-neurologic-improvement-in-treatment-experienced-wilson-disease-patients-at-easl-2026) — Source: Monopar
- 2026-05-19 21:33 EST — [Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-announces-publication-of-phase-2-study-demonstrating-alxn1840-significantly-improves-copper-balance-in-patients-with-wilson-disease) — Source: Monopar
- 2026-05-14 18:00 EST — [Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MNPR/monopar-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Monopar
- 2026-04-19 23:00 EST — [Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026](https://biopharmsignal.com/news/MNPR/monopar-presents-phase-3-data-showing-greater-neurologic-benefit-with-alxn1840-vs-soc-in-wilson-disease-patients-with-neurologic-symptoms-at-aan-2026) — Source: Monopar
- 2026-03-27 17:00 EST — [Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/MNPR/monopar-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Monopar
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)